Literature DB >> 21173438

Joint and separate evaluation of risk reduction: impact on sensitivity to risk reduction magnitude in the context of 4 different risk information formats.

Dorte Gyrd-Hansen1,2, Peder Halvorsen3, Jørgen Nexøe4, Jesper Nielsen1, Henrik Støvring1, Ivar Kristiansen5.   

Abstract

BACKGROUND: When people make choices, they may have multiple options presented simultaneously or, alternatively, have options presented 1 at a time. It has been shown that if decision makers have little experience with or difficulties in understanding certain attributes, these attributes will have greater impact in joint evaluations than in separate evaluations. The authors investigated the impact of separate versus joint evaluations in a health care context in which laypeople were presented with the possibility of participating in risk-reducing drug therapies.
METHODS: In a randomized study comprising 895 subjects aged 40 to 59 y in Odense, Denmark, subjects were randomized to receive information in terms of absolute risk reduction (ARR), relative risk reduction (RRR), number needed to treat (NNT), or prolongation of life (POL), all with respect to heart attack, and they were asked whether they would be willing to receive a specified treatment. Respondents were randomly allocated to valuing the interventions separately (either great effect or small effect) or jointly (small effect and large effect).
RESULTS: Joint evaluation reduced the propensity to accept the intervention that offered the smallest effect. Respondents were more sensitive to scale when faced with a joint evaluation for information formats ARR, RRR, and POL but not for NNT. Evaluability bias appeared to be most pronounced for POL and ARR.
CONCLUSION: Risk information appears to be prone to evaluability bias. This suggests that numeric information on health gains is difficult to evaluate in isolation. Consequently, such information may bear too little weight in separate evaluations of risk-reducing interventions.

Entities:  

Mesh:

Year:  2010        PMID: 21173438     DOI: 10.1177/0272989X10391268

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  5 in total

1.  Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice.

Authors:  Charlotte Gry Harmsen; Ivar Sønbø Kristiansen; Pia Veldt Larsen; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Dorte Ejg Jarbøl
Journal:  Br J Gen Pract       Date:  2014-04       Impact factor: 5.386

Review 2.  Risk as an attribute in discrete choice experiments: a systematic review of the literature.

Authors:  Mark Harrison; Dan Rigby; Caroline Vass; Terry Flynn; Jordan Louviere; Katherine Payne
Journal:  Patient       Date:  2014       Impact factor: 3.883

3.  Medication effectiveness may not be the major reason for accepting cardiovascular preventive medication: a population-based survey.

Authors:  Charlotte Gry Harmsen; Henrik Støvring; Dorte Ejg Jarbøl; Jørgen Nexøe; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Ivar Sønbø Kristiansen
Journal:  BMC Med Inform Decis Mak       Date:  2012-08-09       Impact factor: 2.796

4.  Presenting the improved possibility for staying well might be better than talking about change in risk: use of the non-occurrence probability increase (NOPI).

Authors:  Bertil Hagström; Ronny K Gunnarsson; Mark Rosenfeld
Journal:  Scand J Prim Health Care       Date:  2013-07-29       Impact factor: 2.581

5.  Impact of effectiveness information format on patient choice of therapy and satisfaction with decisions about chronic disease medication: the "Influence of intervention Methodologies on Patient Choice of Therapy (IMPACT)" cluster-randomised trial in general practice.

Authors:  Charlotte Gry Harmsen; Dorte Ejg Jarbøl; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Ivar Sønbø Kristiansen
Journal:  BMC Health Serv Res       Date:  2013-02-25       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.